Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryPain ManagementOpioidRegulatory Approval

FDA Accepts Supplemental Application for Oxycodone Hydrochloride

The FDA's acceptance of the supplemental application for Oxycodone Hydrochloride is a significant regulatory milestone that could strengthen Pharm Assoc.'s market position in pain management. This development necessitates close monitoring of competitive responses and potential shifts in market dynamics.

Published: June 24, 2026
Updated: June 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / Opioid
Company: Pharmaceutical Associates
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Pharmaceutical Associates

Asset

FDA

Indication

Pain Management / Opioid

Status

Approved

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The FDA's acceptance of the supplemental application for Oxycodone Hydrochloride is a significant regulatory milestone that could strengthen Pharm Assoc.'s market position in pain management. This development necessitates close monitoring of competitive responses and potential shifts in market dynamics.

Why it matters

The FDA's acceptance of the supplemental application for Oxycodone Hydrochloride is a significant regulatory milestone that could strengthen Pharm Assoc.'s market position in pain management. This development necessitates close monitoring of competitive responses and potential shifts in market dynamics.

What changed

Regulatory Approval

Analysis

The FDA has accepted a supplemental application for Oxycodone Hydrochloride submitted by Pharm Assoc.

The FDA's acceptance of the supplemental application for Oxycodone Hydrochloride is a significant regulatory milestone that could strengthen Pharm Assoc.'s market position in pain management. This development necessitates close monitoring of competitive responses and potential shifts in market dynamics.

Monitor for further updates on the approval process and any subsequent market actions by competitors.

Related companies & assets

Companies

  • Pharmaceutical Associates →

Assets

  • FDA →
  • Oxycodone Hydrochloride →

Sources & Humanexa intelligence

Source links

  • FDA Accepts Supplemental Application for Oxycodone Hydrochloride ↗

Related Humanexa pages

  • FDA Accepts Supplemental Application for Oxycodone Hydrochloride →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Crescent Pharma Limited

Asset

Crescent

Indication

Cardiovascular / ACE Inhibitor

Status

Under Review

Signal Score

8.4

Regulatoryhigh signal

Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error

Crescent Pharma Limited is recalling a batch of Ramipril 5 mg Capsules due to a potential manufacturing error.

June 24, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

FDA

Indication

Pain Management / Opioid Combination

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Approval Update for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen submitted by Actavis Elizabeth.

June 24, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.